English Overview
The event is to present the relevant unmet needs existing in the dermatology field regarding Atopic dermatitis the suffering on the patients that have actually this disease. The event will have local and International dermatology leaders who will present the content in a very high level of scientific manner. Specifically, the event will consist of having a very good comprehensive review to understand what the mechanism of action of JAK inhibitors is and what are the implications on patients and on the everyday clinical practice of the members among the different situations that they can look at.
This Activity for
- Resident / Fellow
- Physician
- Clinical Pharmacy
What I will learn?
- Current unmet need and disease burden of Atopic Dermatitis
- Why targeting Janus kinase 1 & 2 (JAK 1/2) with Baricitinib improves signs and symptoms of moderate-to-severe atopic dermatitis (AD)
- Safety profile of Baricitinib
- What are the implications of this new oral molecule and what it has for the management of patients with moderate to severe AD
- Why targeting Janus kinase 1 & 2 (JAK 1/2) with Baricitinib improves signs and symptoms of moderate-to-severe atopic dermatitis (AD)
- Safety profile of Baricitinib
- What are the implications of this new oral molecule and what it has for the management of patients with moderate to severe AD
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Now Approved: Treatment for Moderate to Severe Atopic Dermatitis Certificate
Certificate |
Certificate | Free |
VAT 15% Included
